Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT01622621 trial: what clinicians have said so far
Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients Non-Small Lung Cancer
- NCT01622621 ↗
- Terminated
- Mayo Clinic
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT01622621 (high-risk early-stage NSCLC; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT01622621 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Trial of Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients With Early Stage Non-Small Lung Cancer (NSCLC)
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Lung Neoplasms
- Interventions
- Sublobar Resection; Stereotactic Body Radiotherapy (SBRT)
- Arms
- Randomized Sublobar Resection · Active comparator
- Randomized SBRT · Active comparator
- Observation Sublobar Resection · Active comparator
- Observation SBRT · Active comparator
- Enrollment
- 20
- Primary outcomes
- Number of patients alive at 2 years (Overall Survival [OS])
- Sponsor
- Mayo Clinic
- Start
- May 2012
- Primary completion
- Apr 25, 2017
- Results posted
- No
- Registry record
- NCT01622621 · updated Sep 11, 2020